Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Prelude Therapeutics Incorporated stock | $34.76

Learn how to easily invest in Prelude Therapeutics Incorporated stock.

Prelude Therapeutics Incorporated
-$0.68 (-2.08%)

Prelude Therapeutics Incorporated is a biotechnology business based in the US. Prelude Therapeutics Incorporated shares (PRLD) are listed on the NASDAQ and all prices are listed in US Dollars. Prelude Therapeutics Incorporated employs 105 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Prelude Therapeutics Incorporated

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PRLD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Prelude Therapeutics Incorporated stock price (NASDAQ: PRLD)

Use our graph to track the performance of PRLD stocks over time.

Prelude Therapeutics Incorporated shares at a glance

Information last updated 2021-07-28.
Latest market close$34.76
52-week range$23.69 - $95.38
50-day moving average $30.53
200-day moving average $47.39
Wall St. target price$62.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Prelude Therapeutics Incorporated shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Prelude Therapeutics Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Prelude Therapeutics Incorporated price performance over time

Historical closes compared with the close of $34.76 from 2021-05-28

1 week (2021-07-22) N/A
1 month (2021-07-02) 25.17%
3 months (2021-04-30) -16.12%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Prelude Therapeutics Incorporated financials

Gross profit TTM $0
Return on assets TTM -22.04%
Return on equity TTM -36.79%
Profit margin 0%
Book value $7.79
Market capitalisation $1.6 billion

TTM: trailing 12 months

Shorting Prelude Therapeutics Incorporated shares

There are currently 3.6 million Prelude Therapeutics Incorporated shares held short by investors – that's known as Prelude Therapeutics Incorporated's "short interest". This figure is 4.5% up from 3.4 million last month.

There are a few different ways that this level of interest in shorting Prelude Therapeutics Incorporated shares can be evaluated.

Prelude Therapeutics Incorporated's "short interest ratio" (SIR)

Prelude Therapeutics Incorporated's "short interest ratio" (SIR) is the quantity of Prelude Therapeutics Incorporated shares currently shorted divided by the average quantity of Prelude Therapeutics Incorporated shares traded daily (recently around 208516.9600939). Prelude Therapeutics Incorporated's SIR currently stands at 17.04. In other words for every 100,000 Prelude Therapeutics Incorporated shares traded daily on the market, roughly 17040 shares are currently held short.

To gain some more context, you can compare Prelude Therapeutics Incorporated's short interest ratio against those of similar companies.

However Prelude Therapeutics Incorporated's short interest can also be evaluated against the total number of Prelude Therapeutics Incorporated shares, or, against the total number of tradable Prelude Therapeutics Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Prelude Therapeutics Incorporated's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Prelude Therapeutics Incorporated shares in existence, roughly 80 shares are currently held short) or 0.3145% of the tradable shares (for every 100,000 tradable Prelude Therapeutics Incorporated shares, roughly 315 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Prelude Therapeutics Incorporated.

Find out more about how you can short Prelude Therapeutics Incorporated stock.

Prelude Therapeutics Incorporated share dividends

We're not expecting Prelude Therapeutics Incorporated to pay a dividend over the next 12 months.

Prelude Therapeutics Incorporated overview

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware. .

Stocks similar to Prelude Therapeutics Incorporated

Frequently asked questions

What percentage of Prelude Therapeutics Incorporated is owned by insiders or institutions?
Currently 7.18% of Prelude Therapeutics Incorporated shares are held by insiders and 81.543% by institutions.
How many people work for Prelude Therapeutics Incorporated?
Latest data suggests 105 work at Prelude Therapeutics Incorporated.
When does the fiscal year end for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated's fiscal year ends in December.
Where is Prelude Therapeutics Incorporated based?
Prelude Therapeutics Incorporated's address is: 200 Powder Mill Road, Wilmington, DE, United States, 19803
What is Prelude Therapeutics Incorporated's ISIN number?
Prelude Therapeutics Incorporated's international securities identification number is: US74065P1012

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site